{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:03:10Z","timestamp":1780560190178,"version":"3.54.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100021092","name":"University of Yamanashi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100021092","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Cardiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    For high-dose intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD), individualized selection of second-line therapy according to clinical subgroups could be useful to prevent progression of coronary artery abnormalities. We retrospectively analyzed IVIG-resistant KD patients aged\u2009\u2265\u20091 year treated with additional IVIG (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200970) or infliximab (IFX) (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200954) by applying clustering approaches. Consistent with previous studies, fever resolved significantly faster in the IFX group (median 72\u00a0h) than in the second IVIG group (96\u00a0h;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02). However, the incidence of residual coronary artery abnormalities (Z-score\u2009\u2265\u20092.5) at 30 days, 6 months, and 1 year did not differ significantly between the two treatment groups. In the first clustering approach, which was based on ten baseline laboratory variables, the two identified subgroups were not clearly associated with differential treatment responses. In a secondary clustering analysis using four treatment-associated factors (serum sodium, C-reactive protein, total cholesterol, and HDL cholesterol), the three identified stable subgroups were associated with differential treatment responses. Among the three clusters, Cluster 1 showed a favorable response to second IVIG (resistance rate, 7\/36 [19.4%]) but a relatively poor response to IFX (12\/28 [42.9%]). In contrast, Clusters 2 and 3, characterized by dyslipidemia with decreased total cholesterol and HDL cholesterol levels, were resistant to second IVIG (7\/17 [41.2%] and 8\/17 [47.1%], respectively) but relatively sensitive to IFX (0\/7 [0%] and 6\/19 [31.6%], respectively). These findings suggest that IFX may be an effective second-line therapy for IVIG-resistant KD patients with severe dyslipidemia, whereas additional IVIG may remain beneficial for those without dyslipidemia.\n                  <\/jats:p>","DOI":"10.1007\/s00246-026-04323-y","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:21:00Z","timestamp":1780557660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8787-9107","authenticated-orcid":false,"given":"Yuto","family":"Sunaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Hasebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minako","family":"Hoshiai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Hokibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Oshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Sawanobori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Tsuruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Inukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"4323_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1542\/peds.54.3.271","volume":"54","author":"T Kawasaki","year":"1974","unstructured":"Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H (1974) A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 54:271\u2013276","journal-title":"Pediatrics"},{"key":"4323_CR2","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","volume":"135","author":"BW McCrindle","year":"2017","unstructured":"McCrindle BW, Rowley AH, Newburger JW et al (2017) Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 135:e927\u2013e999. https:\/\/doi.org\/10.1161\/CIR.0000000000000484","journal-title":"Circulation"},{"key":"4323_CR3","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1161\/CIR.0000000000001295","volume":"150","author":"PN Jone","year":"2024","unstructured":"Jone PN, Tremoulet A, Choueiter N et al (2024) Update on diagnosis and management of Kawasaki disease: a scientific statement from the American Heart Association. Circulation 150:e481\u2013e500. https:\/\/doi.org\/10.1161\/CIR.0000000000001295","journal-title":"Circulation"},{"key":"4323_CR4","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1056\/NEJM199106063242305","volume":"324","author":"JW Newburger","year":"1991","unstructured":"Newburger JW, Takahashi M, Beiser AS et al (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324:1633\u20131639. https:\/\/doi.org\/10.1056\/NEJM199106063242305","journal-title":"N Engl J Med"},{"key":"4323_CR5","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1097\/00006454-199812000-00009","volume":"17","author":"JC Burns","year":"1998","unstructured":"Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP (1998) Intravenous gamma-globulin treatment and retreatment in Kawasaki disease: US\/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 17:1144\u20131148. https:\/\/doi.org\/10.1097\/00006454-199812000-00009","journal-title":"Pediatr Infect Dis J"},{"key":"4323_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jpeds.2007.12.021","volume":"153","author":"AH Tremoulet","year":"2008","unstructured":"Tremoulet AH, Best BM, Song S et al (2008) Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 153:117\u2013121. https:\/\/doi.org\/10.1016\/j.jpeds.2007.12.021","journal-title":"J Pediatr"},{"key":"4323_CR7","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/S0140-6736(11)61930-2","volume":"379","author":"T Kobayashi","year":"2012","unstructured":"Kobayashi T, Saji T, Otani T et al (2012) Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 379:1613\u20131620. https:\/\/doi.org\/10.1016\/S0140-6736(11)61930-2","journal-title":"Lancet"},{"key":"4323_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.24509\/jpccs.0501G1","volume":"5","author":"M Miura","year":"2021","unstructured":"Miura M, Ayusawa M, Fukazawa R et al (2021) Guidelines for medical treatment of acute Kawasaki disease (2020 revised version). J Pediatric Cardiol Cardiac Surg 5:41\u201373. https:\/\/doi.org\/10.24509\/jpccs.0501G1","journal-title":"J Pediatric Cardiol Cardiac Surg"},{"key":"4323_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jpeds.2013.01.022","volume":"163","author":"T Kobayashi","year":"2013","unstructured":"Kobayashi T, Kobayashi T, Morikawa A et al (2013) Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. J Pediatr 163:521\u2013526. https:\/\/doi.org\/10.1016\/j.jpeds.2013.01.022","journal-title":"J Pediatr"},{"key":"4323_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18387-7","volume":"8","author":"M Mori","year":"2018","unstructured":"Mori M, Hara T, Kikuchi M et al (2018) Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Sci Rep 8:1994. https:\/\/doi.org\/10.1038\/s41598-017-18387-7","journal-title":"Sci Rep"},{"key":"4323_CR11","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S2352-4642(21)00270-4","volume":"5","author":"JC Burns","year":"2021","unstructured":"Burns JC, Roberts SC, Tremoulet AH et al (2021) Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child Adolesc Health 5:852\u2013861. https:\/\/doi.org\/10.1016\/S2352-4642(21)00270-4","journal-title":"Lancet Child Adolesc Health"},{"key":"4323_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/INF.0000000000001039","volume":"35","author":"Y Youn","year":"2016","unstructured":"Youn Y, Kim J, Hong YM, Sohn S (2016) Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatr Infect Dis J 35:457\u2013459. https:\/\/doi.org\/10.1097\/INF.0000000000001039","journal-title":"Pediatr Infect Dis J"},{"key":"4323_CR13","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00431-007-0642-5","volume":"167","author":"M Miura","year":"2008","unstructured":"Miura M, Kohno K, Ohki H, Yoshiba S, Sugaya A, Satoh M (2008) Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. Eur J Pediatr 167:1119\u20131123. https:\/\/doi.org\/10.1007\/s00431-007-0642-5","journal-title":"Eur J Pediatr"},{"key":"4323_CR14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1442-200X.2007.02389.x","volume":"49","author":"R Uehara","year":"2007","unstructured":"Uehara R, Yashiro M, Oki I, Nakamura Y, Yanagawa H (2007) Re-treatment regimens for acute stage of Kawasaki disease patients who failed to respond to initial intravenous immunoglobulin therapy: analysis from the 17th nationwide survey. Pediatr Int 49:427\u2013430. https:\/\/doi.org\/10.1111\/j.1442-200X.2007.02389.x","journal-title":"Pediatr Int"},{"key":"4323_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2025.114479","volume":"279","author":"I Bellicini","year":"2025","unstructured":"Bellicini I, Bainto E, Shimizu C, Burns JC, Tremoulet AH (2025) Cyclosporine treatment in patients with Kawasaki disease and coronary artery aneurysms or treatment resistance. J Pediatr 279:114479. https:\/\/doi.org\/10.1016\/j.jpeds.2025.114479","journal-title":"J Pediatr"},{"key":"4323_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jpeds.2017.10.013","volume":"195","author":"H Masuda","year":"2018","unstructured":"Masuda H, Kobayashi T, Hachiya A et al (2018) Infliximab for the treatment of refractory Kawasaki disease: a nationwide survey in Japan. J Pediatr 195:115-120.e3. https:\/\/doi.org\/10.1016\/j.jpeds.2017.10.013","journal-title":"J Pediatr"},{"key":"4323_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2024.114069","volume":"271","author":"MP Anderson","year":"2024","unstructured":"Anderson MP, Bard D (2024) A gentle introduction to latent class analysis for researchers in pediatrics. J Pediatr 271:114069. https:\/\/doi.org\/10.1016\/j.jpeds.2024.114069","journal-title":"J Pediatr"},{"key":"4323_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jpeds.2020.09.043","volume":"229","author":"JC Burns","year":"2021","unstructured":"Burns JC, DeHaan LL, Shimizu C et al (2021) Temporal clusters of Kawasaki disease cases share distinct phenotypes that suggest response to diverse triggers. J Pediatr 229:48\u201353. https:\/\/doi.org\/10.1016\/j.jpeds.2020.09.043","journal-title":"J Pediatr"},{"key":"4323_CR19","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-051742","volume":"149","author":"SC Boos","year":"2022","unstructured":"Boos SC, Wang M, Karst WA, Hymel KP (2022) Traumatic head injury and the diagnosis of abuse: a cluster analysis. Pediatrics 149:e2021051742. https:\/\/doi.org\/10.1542\/peds.2021-051742","journal-title":"Pediatrics"},{"key":"4323_CR20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S2352-4642(23)00166-9","volume":"7","author":"H Wang","year":"2023","unstructured":"Wang H, Shimizu C, Bainto E et al (2023) Subgroups of children with Kawasaki disease: a data-driven cluster analysis. Lancet Child Adolesc Health 7:697\u2013707. https:\/\/doi.org\/10.1016\/S2352-4642(23)00166-9","journal-title":"Lancet Child Adolesc Health"},{"key":"4323_CR21","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1038\/s41390-025-04205-8","volume":"98","author":"Y Sunaga","year":"2025","unstructured":"Sunaga Y, Hasebe Y, Kikuchi N et al (2025) Heterogeneity in Kawasaki disease patients with coronary artery abnormalities investigated by data-driven cluster analysis. Pediatr Res 98:1809\u20131816. https:\/\/doi.org\/10.1038\/s41390-025-04205-8","journal-title":"Pediatr Res"},{"key":"4323_CR22","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2188\/jea.JE20210132","volume":"31","author":"N Katsumata","year":"2021","unstructured":"Katsumata N, Harama D, Toda T et al (2021) Prevention measures for COVID-19 and changes in Kawasaki disease incidence. J Epidemiol 31:573\u2013580. https:\/\/doi.org\/10.2188\/jea.JE20210132","journal-title":"J Epidemiol"},{"key":"4323_CR23","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/ped.14326","volume":"62","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Ayusawa M, Suzuki H et al (2020) Revision of diagnostic guidelines for Kawasaki disease (6th revised edition). Pediatr Int 62:1135\u20131138. https:\/\/doi.org\/10.1111\/ped.14326","journal-title":"Pediatr Int"},{"key":"4323_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/1744-9987.12754","volume":"23","author":"K Koizumi","year":"2019","unstructured":"Koizumi K, Hoshiai M, Moriguchi T et al (2019) Plasma exchange downregulates activated monocytes and restores regulatory T cells in Kawasaki disease. Ther Apher Dial 23:92\u201398. https:\/\/doi.org\/10.1111\/1744-9987.12754","journal-title":"Ther Apher Dial"},{"key":"4323_CR25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s10047-017-0956-7","volume":"20","author":"T Moriguchi","year":"2017","unstructured":"Moriguchi T, Koizumi K, Matsuda K et al (2017) Plasma exchange for the patients with dilated cardiomyopathy in children is safe and effective in improving both cardiac function and daily activities. J Artif Organs 20:236\u2013243. https:\/\/doi.org\/10.1007\/s10047-017-0956-7","journal-title":"J Artif Organs"},{"key":"4323_CR26","first-page":"401","volume":"5","author":"F Aldi","year":"2023","unstructured":"Aldi F, Hadi F, Rahmi NA, Defit S (2023) Standardscaler\u2019s potential in enhancing breast cancer accuracy using machine learning. J Appl Eng Technol Sci 5:401\u2013413","journal-title":"J Appl Eng Technol Sci"},{"key":"4323_CR27","first-page":"41429","volume":"81","author":"S Bhattacharya","year":"2020","unstructured":"Bhattacharya S, Maddikunta PKR, Hakak S et al (2020) Antlion re-sampling based deep neural network model for classification of imbalanced multimodal stroke dataset. Multimed Tools Appl 81:41429\u201341453","journal-title":"Multimed Tools Appl"},{"key":"4323_CR28","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1080\/00036846.2014.904491","volume":"46","author":"M Arg\u00fcelles","year":"2014","unstructured":"Arg\u00fcelles M, Benavides C, Fern\u00e1ndez I (2014) A new approach to the identification of regional clusters: hierarchical clustering on principal components. Appl Econ 46:2511\u20132519","journal-title":"Appl Econ"},{"key":"4323_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/widm.1219","volume":"7","author":"F Murtagh","year":"2017","unstructured":"Murtagh F, Contreras P (2017) Algorithms for hierarchical clustering: an overview, II. WIREs Data Min Knowl Discov 7:e1219. https:\/\/doi.org\/10.1002\/widm.1219","journal-title":"WIREs Data Min Knowl Discov"},{"key":"4323_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/oxfordjournals.aob.a083391","volume":"18","author":"B Hopkins","year":"1954","unstructured":"Hopkins B, Skellam JG (1954) A new method for determining the type of distribution of plant individuals. Ann Bot 18:213\u2013227","journal-title":"Ann Bot"},{"key":"4323_CR31","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1093\/bioinformatics\/btaa956","volume":"37","author":"M Tang","year":"2021","unstructured":"Tang M, Kaymaz Y, Logeman BL et al (2021) Evaluating single-cell cluster stability using the Jaccard similarity index. Bioinformatics 37:2212\u20132214. https:\/\/doi.org\/10.1093\/bioinformatics\/btaa956","journal-title":"Bioinformatics"},{"key":"4323_CR32","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"4323_CR33","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1006\/cyto.1995.0029","volume":"7","author":"BJ Scallon","year":"1995","unstructured":"Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J (1995) Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7:251\u2013259. https:\/\/doi.org\/10.1006\/cyto.1995.0029","journal-title":"Cytokine"},{"key":"4323_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00246-011-0045-2","volume":"32","author":"LL Blaisdell","year":"2011","unstructured":"Blaisdell LL, Hayman JA, Moran AM (2011) Infliximab treatment for pediatric refractory Kawasaki disease. Pediatr Cardiol 32:15\u201325. https:\/\/doi.org\/10.1007\/s00246-011-0045-2","journal-title":"Pediatr Cardiol"},{"key":"4323_CR35","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/ped.13555","volume":"60","author":"K Koizumi","year":"2018","unstructured":"Koizumi K, Hoshiai M, Katsumata N (2018) Infliximab regulates monocytes and regulatory T cells in Kawasaki disease. Pediatr Int 60:796\u2013802. https:\/\/doi.org\/10.1111\/ped.13555","journal-title":"Pediatr Int"},{"key":"4323_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/INF.0000000000002503","volume":"39","author":"M Miura","year":"2020","unstructured":"Miura M, Kobayashi T, Igarashi T et al (2020) Real-world safety and effectiveness of infliximab in pediatric patients with acute Kawasaki disease: a postmarketing surveillance in Japan (SAKURA study). Pediatr Infect Dis J 39:41\u201347. https:\/\/doi.org\/10.1097\/INF.0000000000002503","journal-title":"Pediatr Infect Dis J"},{"key":"4323_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cyto.2018.11.025","volume":"114","author":"Y Nakashima","year":"2019","unstructured":"Nakashima Y, Nanishi E, Yamamura K et al (2019) Procalcitonin levels predicting the infliximab response of immunoglobulin resistant Kawasaki disease. Cytokine 114:26\u201331. https:\/\/doi.org\/10.1016\/j.cyto.2018.11.025","journal-title":"Cytokine"},{"key":"4323_CR38","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1161\/01.CIR.84.2.625","volume":"84","author":"JW Newburger","year":"1991","unstructured":"Newburger JW, Burns JC, Beiser AS, Loscalzo J (1991) Altered lipid profile after Kawasaki syndrome. Circulation 84:625\u2013631. https:\/\/doi.org\/10.1161\/01.CIR.84.2.625","journal-title":"Circulation"},{"key":"4323_CR39","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0022-3476(05)82404-7","volume":"119","author":"E Salo","year":"1991","unstructured":"Salo E, Pesonen E, Viikari J (1991) Serum cholesterol levels during and after Kawasaki disease. J Pediatr 119:557\u2013561. https:\/\/doi.org\/10.1016\/S0022-3476(05)82404-7","journal-title":"J Pediatr"},{"issue":"10","key":"4323_CR40","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab230","volume":"106","author":"S Shao","year":"2021","unstructured":"Shao S, Zhou K, Liu X et al (2021) Predictive value of serum lipid for intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease. J Clin Endocrinol Metab (10):dgab230. https:\/\/doi.org\/10.1210\/clinem\/dgab230","journal-title":"J Clin Endocrinol Metab"},{"key":"4323_CR41","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0022-2275(20)32153-2","volume":"40","author":"HE Henderson","year":"1999","unstructured":"Henderson HE, Kastelein JJP, Zwinderman AH et al (1999) Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins. J Lipid Res 40:735\u2013743. https:\/\/doi.org\/10.1016\/S0022-2275(20)32153-2","journal-title":"J Lipid Res"},{"key":"4323_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-018-0243-z","volume":"16","author":"XY Zhang","year":"2018","unstructured":"Zhang XY, Yang TT, Hu XF, Wen Y, Fang F, Lu HL (2018) Circulating adipokines are associated with Kawasaki disease. Pediatr Rheumatol Online J 16:33. https:\/\/doi.org\/10.1186\/s12969-018-0243-z","journal-title":"Pediatr Rheumatol Online J"},{"key":"4323_CR43","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s10067-023-06502-1","volume":"42","author":"Y Sunaga","year":"2023","unstructured":"Sunaga Y, Watanabe A, Katsumata N et al (2023) A simple scoring model based on machine learning predicts intravenous immunoglobulin resistance in Kawasaki disease. Clin Rheumatol 42:1351\u20131361. https:\/\/doi.org\/10.1007\/s10067-023-06502-1","journal-title":"Clin Rheumatol"},{"key":"4323_CR44","doi-asserted-by":"publisher","first-page":"202","DOI":"10.5551\/jat.13.202","volume":"13","author":"H Arai","year":"2006","unstructured":"Arai H, Yamamoto A, Matsuzawa Y et al (2006) Prevalence of metabolic syndrome in the general Japanese population in 2000. J Atheroscler Thromb 13:202\u2013208. https:\/\/doi.org\/10.5551\/jat.13.202","journal-title":"J Atheroscler Thromb"},{"key":"4323_CR45","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1007\/s00467-006-0086-6","volume":"21","author":"T Watanabe","year":"2006","unstructured":"Watanabe T, Abe Y, Sato S et al (2006) Hyponatremia in Kawasaki disease. Pediatr Nephrol 21:778\u2013781. https:\/\/doi.org\/10.1007\/s00467-006-0086-6","journal-title":"Pediatr Nephrol"},{"key":"4323_CR46","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/ped.14036","volume":"62","author":"K Miura","year":"2020","unstructured":"Miura K, Harita Y, Takahashi N et al (2020) Nonosmotic secretion of arginine vasopressin and salt loss in hyponatremia in Kawasaki disease. Pediatr Int 62:1074\u20131080. https:\/\/doi.org\/10.1111\/ped.14036","journal-title":"Pediatr Int"},{"key":"4323_CR47","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S2352-4642(18)30293-1","volume":"2","author":"K Miyata","year":"2018","unstructured":"Miyata K, Kaneko T, Morikawa Y et al (2018) Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study. Lancet Child Adolesc Health 2:855\u2013862. https:\/\/doi.org\/10.1016\/S2352-4642(18)30293-1","journal-title":"Lancet Child Adolesc Health"},{"key":"4323_CR48","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/S0140-6736(18)32003-8","volume":"393","author":"H Hamada","year":"2019","unstructured":"Hamada H, Suzuki H, Onouchi Y et al (2019) Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet 393:1128\u20131137. https:\/\/doi.org\/10.1016\/S0140-6736(18)32003-8","journal-title":"Lancet"},{"key":"4323_CR49","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00431-008-0727-9","volume":"168","author":"K Okada","year":"2009","unstructured":"Okada K, Hara J, Maki I et al (2009) Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr 168:181\u2013185. https:\/\/doi.org\/10.1007\/s00431-008-0727-9","journal-title":"Eur J Pediatr"},{"key":"4323_CR50","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1542\/peds.2011-0148","volume":"129","author":"S Ogata","year":"2012","unstructured":"Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M (2012) Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics 129:e17\u2013e23. https:\/\/doi.org\/10.1542\/peds.2011-0148","journal-title":"Pediatrics"},{"key":"4323_CR51","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00431-006-0223-z","volume":"166","author":"T Sano","year":"2007","unstructured":"Sano T, Kurotobi S, Matsuzaki K et al (2007) Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 166:131\u2013137. https:\/\/doi.org\/10.1007\/s00431-006-0223-z","journal-title":"Eur J Pediatr"},{"key":"4323_CR52","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00380-020-01622-z","volume":"35","author":"T Kanai","year":"2020","unstructured":"Kanai T, Kakeshita S, Kawamura Y et al (2020) The combination of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as a novel predictor of intravenous immunoglobulin resistance in patients with Kawasaki disease: a multicenter study. Heart Vessels 35:1463\u20131472. https:\/\/doi.org\/10.1007\/s00380-020-01622-z","journal-title":"Heart Vessels"}],"container-title":["Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-026-04323-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00246-026-04323-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-026-04323-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:21:05Z","timestamp":1780557665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00246-026-04323-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":52,"alternative-id":["4323"],"URL":"https:\/\/doi.org\/10.1007\/s00246-026-04323-y","relation":{},"ISSN":["0172-0643","1432-1971"],"issn-type":[{"value":"0172-0643","type":"print"},{"value":"1432-1971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"22 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Research Ethics Committee of University of Yamanashi Hospital (Approval Number 1698). Informed consent was obtained from the parents or guardians of the children who served as subjects of the investigation and, when appropriate, assent from the subjects themselves. Details that might disclose the identity of the subjects under study have been omitted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from the individual patients or their parents.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Informed consent was obtained from the individual patients or their parents.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}